Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients With Refractory or Recurrent CNS Tumours.
Phase of Trial: Phase I
Latest Information Update: 06 May 2015
At a glance
- Drugs PTC 299 (Primary)
- Indications CNS cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 03 May 2015 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 17 Apr 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 02 May 2011 Planned end date changed from 1 Feb 2011 to 1 May 2012 as reported by ClinicalTrials.gov.